Developer docs
API playgroundTry for free, no card

Search company profiles

Medmain

Full company profile

uuid0002b1q

Namestring
Medmain
Legal namestring
Medmain Inc.
Websiteurl
en.medmain.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Medmain Inc. is a Japanese healthcare technology company founded in January 2018 in Fukuoka, Japan, that develops and operates PidPort, an AI-powered cloud platform for digital pathology. The platform combines three integrated modules: deep learning–based AI analysis for pathological screening across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin), telepathology for remote pathological diagnosis via cloud networks, and cloud-based storage and management of digitized pathology specimens. The company's underlying technology uses proprietary transfer learning and weakly supervised learning to develop pathology AI models, with disclosed accuracy of ROC-AUC 0.94–0.99 across cancer detection tasks. Medmain also offers the Imaging Center service for physical-to-digital conversion of pathology slides and Medteria, a separate cloud service for medical students.

The company operates a subscription-based SaaS revenue model with no initial equipment fees, selling primarily through direct enterprise sales to hospitals and medical institutions, supplemented by channel partnerships. In Japan, distribution occurs via a capital and business alliance with PSP Corporation, which provides access to roughly 2,200 medical institutions and 22%+ of the Japanese PACS market. Internationally, Medmain has signed MOUs with major Vietnamese hospitals (Bach Mai, E Hospital, Thai Nguyen A, Ha Dong General) and partners with SMC Co., Ltd. for Asia distribution. The company has secured ISO/IEC 27001:2022 (November 2024), ISO 13485:2016 (January 2025), and a Japanese First-Class Marketing License for Medical Devices (July 2024). According to a February 2026 M&A report, Medmain was acquired by PSP Corporation.

Short descriptiontext

Medmain Inc. is a Fukuoka, Japan–based healthcare technology company developing PidPort, an AI-powered cloud platform for digital pathology that provides AI-based cancer screening, telepathology, and slide image storage for hospitals and medical institutions, distributed in Japan via PSP Corporation and internationally through channel partners.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFukuoka, Japan
HQ citystring
Fukuoka
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI pathology diagnostics, digital pathology platform, telepathology software, medical image analysis, cloud-based pathology
Industry4 codes
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Prepackaged Software7372
Product category
Digital Pathology Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1PidPort Subscription
TypeSubscription Recurring
Description

Cloud-based SaaS subscription model for pathological image diagnosis platform. Access via web application without initial equipment fees. Revenue generated from subscription fees for AI analysis, telepathology, and cloud storage services.

en.medmain.com
2Imaging Center Services
TypeSubscription Recurring
Description

High-quality digital imaging services for pathological tissue specimens using on-site scanners, with secure cloud-based storage. Revenue from digitization and storage services.

en.medmain.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Cloud-based subscription with no initial equipment fees
ModelSubscriptionBilling cadenceMonthly
Notes

As long as there is Internet connection, the cloud service can be accessed any time, without any initial fee such as the introduction of equipments.

en.medmain.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1PidPort
Description

AI-powered cloud system for digital pathology support with features including AI analysis, telepathology, and cloud storage for pathological specimens

en.medmain.com
+2 more records
Core offering1 text field

Medmain develops and operates PidPort, an AI-powered cloud platform for digital pathology support that uses proprietary deep learning to perform super-precise, instantaneous screening of pathologic tissue and cells across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin). PidPort combines three integrated capabilities — AI-based pathological screening, telepathology (remote pathological diagnosis over a global cloud network), and cloud-based storage and management of digitized pathologic specimens. The offering is delivered as a SaaS subscription accessible via web application with no upfront equipment fees, and is supported by an Imaging Center service that digitizes histopathological specimens on site.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ROC-AUC up to 0.99 for various cancer detection tasks including gastric, colonic, and lung cancer classification
+3 more records
Product overview1 text field

Medmain operates as a medical software company offering a unified product ecosystem centered on PidPort, an AI-powered cloud platform for digital pathology. The core PidPort platform combines three integrated modules: AI Analysis (deep learning-based pathological screening for multiple organ cancer detection), Telepathology (globally-linked remote pathological diagnosis via cloud networks), and Cloud Storage (digitization and management of pathologic specimen images). The Imaging Center service provides the digitization infrastructure that feeds into PidPort's cloud platform. Additionally, Medmain developed Medteria as a separate cloud service for medical education. The company has also developed specialized AI models for specific applications such as Ki-67 labeling index measurement in immunohistochemistry specimens.

Product and service4 records
1PidPort Digital Pathology Platform
CategoryDigital Pathology Software
Description

AI-powered cloud platform for digital pathology that delivers super-precise, instantaneous AI-based pathological screening of tissue and cells, telepathology-enabled remote pathological diagnosis, and cloud-based storage and management of digitized pathologic specimens. Built for hospitals, medical institutions, and pathology departments.

2Imaging Center
CategorySlide Digitization and Storage Service
Description

High-quality digitization service for histopathological tissue specimens using specialized scanners, with secure cloud-based storage and web-based viewing platform for pathologic image management. Designed for hospitals and pathology labs that need to convert physical specimens into high-quality digital images and feed them into PidPort's cloud platform.

3Medteria
CategoryMedical Education Cloud Service
Description

Tailored cloud service for medical students that organizes and manages study materials to support efficient access to required learning information. Used by medical schools in Japan as an education technology platform.

4Ki-67 AI for Immunohistochemistry Analysis
CategoryPathology AI Module
Description

AI model that automatically detects Ki-67 positive and negative cells by identifying cell nuclei and performing cell-level classification on whole-slide immunohistochemistry images, then calculates the labeling index to support cancer prognosis assessment.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Ha Dong General Hospital
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-17
Description

Level I municipal hospital in Hanoi implementing PidPort for research and pilot testing. MOU signed with SMC and hospital with representatives from Embassy of Japan in Vietnam present.

en.medmain.com
2Bach Mai Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

MOU for comprehensive cooperation in digital pathology support and utilization of medical AI in Vietnam. Medmain will lead introduction, pilot implementation, and nationwide deployment of PidPort across Vietnamese medical institutions.

en.medmain.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

MOU partner for digital transformation of pathology and AI cancer diagnostics. E Hospital is a major medical institution under Vietnamese Ministry of Health with focus on digitalization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

MOU partner for digital pathology and AI adoption in cytology, histopathology, and lesion classification. Regional hub for medical care and education in northern Vietnam.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-01
Description

Partnership agreement signed to promote research and application of AI in pathological diagnosis in Vietnam. SMC supports medical tourism and overseas expansion of Japanese medical technologies.

6Japan Innovation Campus (METI)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-11-14
Description

Selected as coworking member of Japan's new startup base in Silicon Valley established by Ministry of Economy, Trade and Industry. Provides access to local VCs, accelerators, and Stanford/UC Berkeley resources for US market expansion.

en.medmain.com
7U.S. Market Gateway Accelerator for BioSciences and MedTech
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-09-13
Description

Selected for WorldUpstart accelerator program sponsored by US Market Gateway, providing support for business development in the US market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-07-26
Description

Capital and business alliance partner with ~2,200 medical institution customers and 22%+ market share in Japan PACS market. PSP integrates Medmain's pathology AI into its infrastructure platforms (NOBORI cloud storage, ICHIGO remote image diagnosis) and sells Medmain products to its customer base.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based pathology AI company with the first FDA-authorized AI product in pathology (Prostate). Directly comparable to Medmain in applying deep learning to whole slide images for cancer detection and offering enterprise pathology AI solutions to hospitals.

TypeDirect peer
Description

Boston-based AI pathology company offering both diagnostic AI products and biopharma research services. Closely comparable to Medmain's PidPort in using deep learning on histopathology images to support pathologist decision-making across multiple cancer types.

TypeDirect peer
Description

Israel-based pathology AI platform deployed across multiple hospital systems in Europe and the US for cancer detection across breast, prostate, and gastrointestinal tissues. Directly competes with PidPort as an enterprise AI pathology screening and triage platform.

TypeDirect peer
Description

US-based digital pathology platform offering Concentriq, a cloud-based workflow and AI platform for pathology laboratories. Comparable to Medmain's PidPort in providing cloud-hosted pathology image management combined with AI-based analysis tools.

TypeDirect peer
Description

France-based AI biotech building pathology and multimodal AI models for cancer research and diagnostics, including the Klarity digital pathology product. Comparable to Medmain for AI-driven histopathology analysis serving hospitals and research institutions.

TypeEmerging player
Description

Netherlands-based pathology AI company developing deep learning models for kidney and prostate biopsy assessment. Emerging player with partial overlap to Medmain's organ-specific pathology AI focus and ISO 13485-style regulatory positioning.

TypeBroad incumbent
Description

Japan-headquartered global leader in whole-slide imaging scanners (NanoZoomer) and a major participant in digital pathology infrastructure. Comparable to Medmain as part of the same Japan digital pathology ecosystem and potential imaging input source for PidPort's cloud workflow.

TypeBroad incumbent
Description

Global medtech incumbent whose IntelliSite Pathology Solution is one of the most widely deployed whole-slide imaging and pathology workflow platforms. Competes with PidPort at the enterprise hospital level as a broader imaging and informatics portfolio vendor.

TypeBroad incumbent
Description

Global pathology vendor offering Aperio digital pathology scanners and image management systems used by hospitals and research institutions. Overlaps with Medmain as a digital pathology workflow incumbent with broader hardware and software stack.

TypeBroad incumbent
Description

Japan-headquartered histology and pathology equipment vendor with global reach in tissue processing, embedding, and slide preparation systems. Comparable as part of the broader pathology workflow stack where Medmain's Imaging Center and AI analysis plug in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medmain

Digital Pathology Softwareen.medmain.com

Medmain Inc. is a Fukuoka, Japan–based healthcare technology company developing PidPort, an AI-powered cloud platform for digital pathology that provides AI-based cancer screening, telepathology, and slide image storage for hospitals and medical institutions, distributed in Japan via PSP Corporation and internationally through channel partners.

What Medmain does

Medmain Inc. is a Japanese healthcare technology company founded in January 2018 in Fukuoka, Japan, that develops and operates PidPort, an AI-powered cloud platform for digital pathology. The platform combines three integrated modules: deep learning–based AI analysis for pathological screening across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin), telepathology for remote pathological diagnosis via cloud networks, and cloud-based storage and management of digitized pathology specimens. The company's underlying technology uses proprietary transfer learning and weakly supervised learning to develop pathology AI models, with disclosed accuracy of ROC-AUC 0.94–0.99 across cancer detection tasks. Medmain also offers the Imaging Center service for physical-to-digital conversion of pathology slides and Medteria, a separate cloud service for medical students.

The company operates a subscription-based SaaS revenue model with no initial equipment fees, selling primarily through direct enterprise sales to hospitals and medical institutions, supplemented by channel partnerships. In Japan, distribution occurs via a capital and business alliance with PSP Corporation, which provides access to roughly 2,200 medical institutions and 22%+ of the Japanese PACS market. Internationally, Medmain has signed MOUs with major Vietnamese hospitals (Bach Mai, E Hospital, Thai Nguyen A, Ha Dong General) and partners with SMC Co., Ltd. for Asia distribution. The company has secured ISO/IEC 27001:2022 (November 2024), ISO 13485:2016 (January 2025), and a Japanese First-Class Marketing License for Medical Devices (July 2024). According to a February 2026 M&A report, Medmain was acquired by PSP Corporation.

Medmain firmographics

Firmographics
Name
Medmain
Legal name
Medmain Inc.
Website
https://en.medmain.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Medmain Inc. is a Fukuoka, Japan–based healthcare technology company developing PidPort, an AI-powered cloud platform for digital pathology that provides AI-based cancer screening, telepathology, and slide image storage for hospitals and medical institutions, distributed in Japan via PSP Corporation and internationally through channel partners.
Ownership category
akta.pro rank

Medmain industry classification

Industry
Product category
Digital Pathology Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • AI pathology diagnostics
  • Digital pathology platform
  • Telepathology software
  • Medical image analysis
  • Cloud-based pathology

Where Medmain is headquartered

Location

Headquarters

HQ city
Fukuoka
HQ country
Japan
HQ region
Asia

Offices3 records

Markets served

Medmain business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. PidPort Subscription: Cloud-based SaaS subscription model for pathological image diagnosis platform. Access via web application without initial equipment fees. Revenue generated from subscription fees for AI analysis, telepathology, and cloud storage services.
  2. Imaging Center Services: High-quality digital imaging services for pathological tissue specimens using on-site scanners, with secure cloud-based storage. Revenue from digitization and storage services.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyCloud-based subscription with no initial equipment fees

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Medmain product offering

Product offering

Core offering

Medmain develops and operates PidPort, an AI-powered cloud platform for digital pathology support that uses proprietary deep learning to perform super-precise, instantaneous screening of pathologic tissue and cells across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin). PidPort combines three integrated capabilities — AI-based pathological screening, telepathology (remote pathological diagnosis over a global cloud network), and cloud-based storage and management of digitized pathologic specimens. The offering is delivered as a SaaS subscription accessible via web application with no upfront equipment fees, and is supported by an Imaging Center service that digitizes histopathological specimens on site.

Product overview

Medmain operates as a medical software company offering a unified product ecosystem centered on PidPort, an AI-powered cloud platform for digital pathology. The core PidPort platform combines three integrated modules: AI Analysis (deep learning-based pathological screening for multiple organ cancer detection), Telepathology (globally-linked remote pathological diagnosis via cloud networks), and Cloud Storage (digitization and management of pathologic specimen images). The Imaging Center service provides the digitization infrastructure that feeds into PidPort's cloud platform. Additionally, Medmain developed Medteria as a separate cloud service for medical education. The company has also developed specialized AI models for specific applications such as Ki-67 labeling index measurement in immunohistochemistry specimens.

Differentiator

Problem solved

Functional benefit

Brands

  • PidPort: AI-powered cloud system for digital pathology support with features including AI analysis, telepathology, and cloud storage for pathological specimens
  • Medteria
  • Imaging Center

Products and services

  • PidPort Digital Pathology Platform AI-powered cloud platform for digital pathology that delivers super-precise, instantaneous AI-based pathological screening of tissue and cells, telepathology-enabled remote pathological diagnosis, and cloud-based storage and management of digitized pathologic specimens. Built for hospitals, medical institutions, and pathology departments.
  • Imaging Center High-quality digitization service for histopathological tissue specimens using specialized scanners, with secure cloud-based storage and web-based viewing platform for pathologic image management. Designed for hospitals and pathology labs that need to convert physical specimens into high-quality digital images and feed them into PidPort's cloud platform.
  • Medteria Tailored cloud service for medical students that organizes and manages study materials to support efficient access to required learning information. Used by medical schools in Japan as an education technology platform.
  • Ki-67 AI for Immunohistochemistry Analysis AI model that automatically detects Ki-67 positive and negative cells by identifying cell nuclei and performing cell-level classification on whole-slide immunohistochemistry images, then calculates the labeling index to support cancer prognosis assessment.

Quantifiable outcome

  • ROC-AUC up to 0.99 for various cancer detection tasks including gastric, colonic, and lung cancer classification
  • +3 more outcomes

Companies that use Medmain

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Medmain technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Medmain partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major and core.

  • Ha Dong General HospitalmajorStrategic or Co-development Partner · 17 October 2025Level I municipal hospital in Hanoi implementing PidPort for research and pilot testing. MOU signed with SMC and hospital with representatives from Embassy of Japan in Vietnam present.
  • Bach Mai HospitalcoreStrategic or Co-development Partner · 14 August 2025MOU for comprehensive cooperation in digital pathology support and utilization of medical AI in Vietnam. Medmain will lead introduction, pilot implementation, and nationwide deployment of PidPort across Vietnamese medical institutions.
  • E HospitalcoreStrategic or Co-development Partner · 14 August 2025MOU partner for digital transformation of pathology and AI cancer diagnostics. E Hospital is a major medical institution under Vietnamese Ministry of Health with focus on digitalization.
  • Thai Nguyen A HospitalcoreStrategic or Co-development Partner · 14 August 2025MOU partner for digital pathology and AI adoption in cytology, histopathology, and lesion classification. Regional hub for medical care and education in northern Vietnam.
  • SMC Co., Ltd. (Medical Tourism Japan Division)coreChannel Partner/ Reseller/ Distributor · 1 July 2025Partnership agreement signed to promote research and application of AI in pathological diagnosis in Vietnam. SMC supports medical tourism and overseas expansion of Japanese medical technologies.
  • Japan Innovation Campus (METI)majorStrategic or Co-development Partner · 14 November 2023Selected as coworking member of Japan's new startup base in Silicon Valley established by Ministry of Economy, Trade and Industry. Provides access to local VCs, accelerators, and Stanford/UC Berkeley resources for US market expansion.
  • U.S. Market Gateway Accelerator for BioSciences and MedTechmajorStrategic or Co-development Partner · 13 September 2023Selected for WorldUpstart accelerator program sponsored by US Market Gateway, providing support for business development in the US market.
  • PSP CorporationcoreChannel Partner/ Reseller/ Distributor · 26 July 2022Capital and business alliance partner with ~2,200 medical institution customers and 22%+ market share in Japan PACS market. PSP integrates Medmain's pathology AI into its infrastructure platforms (NOBORI cloud storage, ICHIGO remote image diagnosis) and sells Medmain products to its customer base.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Medmain competitors and assessment

Company assessment

Direct peers

  • Paige.AI: US-based pathology AI company with the first FDA-authorized AI product in pathology (Prostate). Directly comparable to Medmain in applying deep learning to whole slide images for cancer detection and offering enterprise pathology AI solutions to hospitals.
  • PathAI: Boston-based AI pathology company offering both diagnostic AI products and biopharma research services. Closely comparable to Medmain's PidPort in using deep learning on histopathology images to support pathologist decision-making across multiple cancer types.
  • Ibex Medical Analytics: Israel-based pathology AI platform deployed across multiple hospital systems in Europe and the US for cancer detection across breast, prostate, and gastrointestinal tissues. Directly competes with PidPort as an enterprise AI pathology screening and triage platform.
  • Proscia: US-based digital pathology platform offering Concentriq, a cloud-based workflow and AI platform for pathology laboratories. Comparable to Medmain's PidPort in providing cloud-hosted pathology image management combined with AI-based analysis tools.
  • Owkin: France-based AI biotech building pathology and multimodal AI models for cancer research and diagnostics, including the Klarity digital pathology product. Comparable to Medmain for AI-driven histopathology analysis serving hospitals and research institutions.

Emerging players

  • Aiosyn: Netherlands-based pathology AI company developing deep learning models for kidney and prostate biopsy assessment. Emerging player with partial overlap to Medmain's organ-specific pathology AI focus and ISO 13485-style regulatory positioning.

Broad incumbents

  • Hamamatsu Photonics: Japan-headquartered global leader in whole-slide imaging scanners (NanoZoomer) and a major participant in digital pathology infrastructure. Comparable to Medmain as part of the same Japan digital pathology ecosystem and potential imaging input source for PidPort's cloud workflow.
  • Philips (Digital Pathology): Global medtech incumbent whose IntelliSite Pathology Solution is one of the most widely deployed whole-slide imaging and pathology workflow platforms. Competes with PidPort at the enterprise hospital level as a broader imaging and informatics portfolio vendor.
  • Leica Biosystems: Global pathology vendor offering Aperio digital pathology scanners and image management systems used by hospitals and research institutions. Overlaps with Medmain as a digital pathology workflow incumbent with broader hardware and software stack.
  • Sakura Finetek: Japan-headquartered histology and pathology equipment vendor with global reach in tissue processing, embedding, and slide preparation systems. Comparable as part of the broader pathology workflow stack where Medmain's Imaging Center and AI analysis plug in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Medmain social profiles

Digital presence

Medmain compliance and trust

Trust signal

Compliance2 records

Medmain financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medmain leadership team

Management profile

Number of profiles

Profiles5 records

Medmain subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Medmain funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medmain M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medmain

What does Medmain do?

Medmain develops and operates PidPort, an AI-powered cloud platform for digital pathology support that uses proprietary deep learning to perform super-precise, instantaneous screening of pathologic tissue and cells across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin). PidPort combines three integrated capabilities — AI-based pathological screening, telepathology (remote pathological diagnosis over a global cloud network), and cloud-based storage and management of digitized pathologic specimens. The offering is delivered as a SaaS subscription accessible via web application with no upfront equipment fees, and is supported by an Imaging Center service that digitizes histopathological specimens on site.

Is Medmain a public or private company?

Medmain is a private company. It is classified as corporate owned and is currently acquired.

When was Medmain founded?

Medmain was founded in 2018. It employs 11 to 50 people.

Where is Medmain based?

Medmain is headquartered in Fukuoka, Japan, in the Asia region.

How does Medmain make money?

Two revenue lines are on record. PidPort Subscription is the primary driver. The others are imaging Center Services.

Who are Medmain's main competitors?

Direct peers on record are Paige.AI, PathAI, Ibex Medical Analytics, Proscia and Owkin. Aiosyn is listed as an emerging player. Broad incumbents are Hamamatsu Photonics, Philips (Digital Pathology), Leica Biosystems and Sakura Finetek.

Does Medmain have an API?

No public API is recorded for Medmain.

What industry is Medmain in?

Medmain's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 54151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Prtimesメドメイン、個人向け病理画像クラウド「PidPort Personalプラン」を提供開始、3か月無料キャンペーンを実施Medmain Inc. launched the PidPort Personal Plan, a pathology image cloud service for individuals, offering a 3-month free trial of the 50GB plan. A coupon code provides a 3,980 yen discount for 100GB or 250GB plans, valid until December 31, 2026. The service supports browser-based access and future AI analysis features.openPR.comJapan Telemedicine Market Expected to Reach US$ 25.87 Billion by 2033 as Digital Healthcare and Remote Patient Care Accelerate NationwideThe Japan Telemedicine Market is projected to grow from US$ 5,142.91 million in 2024 to US$ 25,867.49 million by 2033, expanding at a CAGR of 19.5% during the forecast period (2025–2033). The growth is driven by Japan's aging demographics, advancements in healthcare IT infrastructure, and government initiatives supporting digital health services, accelerating adoption across hospitals, clinics, and home-care settings. Key companies operating in the market include Nihon Kohden Corporation, MEDLEY, Inc., Terumo Corporation, M3, Inc., Medmain, PK Telehealth, NTT Data Inc., and Sony Corporation, all investing in AI-enabled telehealth platforms and remote patient monitoring technologies.Signify ResearchM&A, AI Integration & Enterprise Imaging DevelopmentsFebruary 2026 saw multiple M&A transactions and strategic developments in the medical imaging informatics sector, including Nexus Enterprise Imaging (PE-backed) taking operational control of Apollo Enterprise Imaging, PSP Corporation completing its acquisition of Japanese pathology AI specialist Medmain, and HealthMark Group acquiring image management vendor Purview. DeepHealth secured CE Mark approval for its TechLive Remote Scanning solution following prior FDA clearance, while the Veterans Health Administration cancelled its NextGen PACS framework for the National Teleradiology Program, leaving Intelerad as its existing solution provider.PlugandplaytechcenterAccelerating Medical DX and Expanding Global Access to PathologyMedmain is addressing the global shortage of pathologists by offering an AI-powered cloud platform called PidPort, which integrates digital slide management and remote collaboration for improved diagnostic accuracy. The technology has been adopted by medical universities in Japan and aims to expand into emerging markets with underdeveloped healthcare infrastructure, facilitating remote diagnoses and cancer detection. The company, supported by investments from Plug and Play, is focused on democratizing access to advanced medical diagnostics globally.MedmainMedmain inc.Medmain, a Japanese pathology AI startup, raised 3.3 million USD in a third-party allotment of shares, with One Capital as lead investor. The round brings total equity funding to 18 million USD, with Niremia Collective and Plug and Play participating.PR NewswireMedmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTechMedmain Inc., a Japanese medtech startup offering AI-powered digital pathology solutions, has been selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech, a program sponsored by WorldUpstart, LLC designed to help international medical technology companies enter and expand in the U.S. market. Through this program, Medmain will receive advisory support covering FDA regulatory filings, marketing strategies, intellectual property planning, financing, and business alliance development, while also gaining the opportunity to present its PidPort platform at the Philadelphia Alliance for Capital and Technology Conference in November. The company, which has also secured funding from Japan's Agency for Medical Research and Development (AMED), aims to leverage technology to improve global access to medical services.MedmainMedmain inc.Medmain Inc. has established a capital and business alliance with PSP Corporation, raising 300 million yen through a third-party share allotment to accelerate digital pathology initiatives. Under the partnership, Medmain's AI-based PidPort system will be integrated into PSP's infrastructure platforms, while PSP will distribute Medmain products to its customer base.